EPS for Gemphire Therapeutics Inc. (GEMP) Expected At $-0.72

March 8, 2018 - By reb123z

 EPS for Gemphire Therapeutics Inc. (GEMP) Expected At $ 0.72

Analysts expect Gemphire Therapeutics Inc. (NASDAQ:GEMP) to report $-0.72 EPS on March, 21.They anticipate $0.06 EPS change or 7.69 % from last quarter’s $-0.78 EPS. After having $-0.82 EPS previously, Gemphire Therapeutics Inc.’s analysts see -12.20 % EPS growth. The stock decreased 7.03% or $0.58 during the last trading session, reaching $7.67. About 131,851 shares traded or 17.22% up from the average. Gemphire Therapeutics Inc. (NASDAQ:GEMP) has 0.00% since March 8, 2017 and is . It has underperformed by 16.70% the S&P500.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) Ratings Coverage

Among 3 analysts covering Gemphire Therapeutics (NASDAQ:GEMP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Gemphire Therapeutics had 3 analyst reports since August 30, 2016 according to SRatingsIntel. Canaccord Genuity initiated Gemphire Therapeutics Inc. (NASDAQ:GEMP) rating on Tuesday, August 30. Canaccord Genuity has “Buy” rating and $17 target. The stock of Gemphire Therapeutics Inc. (NASDAQ:GEMP) has “Buy” rating given on Tuesday, August 30 by Jefferies. RBC Capital Markets initiated the stock with “Outperform” rating in Tuesday, August 30 report.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis . The company has market cap of $105.66 million. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. It currently has negative earnings.

More recent Gemphire Therapeutics Inc. (NASDAQ:GEMP) news were published by: Streetinsider.com which released: “Gemphire Therapeutics (GEMP) Prices 3.14M Common Stock Offering at $7/Share” on February 08, 2018. Also Gurufocus.com published the news titled: “Gemphire Therapeutics Inc (GEMP) Interim President & CEO Steven R. Ph.d …” on February 12, 2018. Streetinsider.com‘s news article titled: “Gemphire Therapeutics (GEMP) to Offer Common Stock” with publication date: February 07, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: